Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia

Table 2

Reported side effects and toxicities associated with TCH versus TCHP. The numbers reflect percentages of patients with recorded side effects and toxicities in their electronic medical files. Mild, moderate, and severe side effects are correlated with CTCAE grade 1, grades 2-3, and grade 4 side effects, respectively.

Side effect/toxicity	TCH group				TCHP group
Severity	Total (%)	Mild (%)	Moderate (%)	Severe (%)	Total (%)	Mild (%)	Moderate (%)	Severe (%)
General side effects
Fatigue	36	34	2	2	40	36	2	2
Fever	14	12	1	2	16	13	1	2
Anorexia	21	14	4	3	16	11	4	1
Nausea	21	12	8	1	22	14	7	1
Dry eyes	5	2	2	1	8	3	4	1
Gastrointestinal symptoms
Diarrhea	54	48	4	2	55	49	4	2
Mucositis	8	4	2	2	7	3	2	2
Respiratory system side effects
Cough	9	5	2	2	8	2	4	2
Dermatological side effects
Rash	6	3	2	1	4	2	1	1
Musculoskeletal side effects
Myalgias	12	6	2	4	12	5	3	4
Neurological side effects
Neuropathy	4	1	2	1	3	1	1	1
Haematological side effects
Febrile neutropenia	13	2	0	1	4	3	1	0